This is a single-center observational registry study aiming to establish a structured clinical and multimodal imaging database for cardiovascular-kidney-metabolic (CKM) populations and to support lifecycle follow-up and outcome management. Adult patients aged 18-80 years with cardiovascular, kidney, and/or metabolic diseases or key data for CKM phenotyping will be enrolled at the First Affiliated Hospital of Fujian Medical University. The study integrates retrospective data entry and prospective follow-up, including clinical records, laboratory tests, medications, electrocardiography, echocardiography, vascular function assessment, carotid and abdominal ultrasound, bone density, coronary CTA and post-processing data. The primary outcome is the first occurrence of a cardiorenal composite endpoint. Participants will be followed for up to 5 years through active annual follow-up and passive monthly data updates to support risk stratification, real-world evidence generation, and CKM management pathway optimization.
Age 18 years or older.
Inpatient record available at the First Affiliated Hospital of Fujian Medical University with retrievable identifiers for data linkage.
Cardiovascular disease, kidney disease, metabolic disease, or key examination/laboratory information supporting CKM phenotyping.
Willingness to participate and provision of written informed consent.
Refusal to provide written informed consent.
Severe psychiatric disease or cognitive impairment precluding participation.
End-stage disease with expected survival less than 1 year.
Long-term absence more than 6 months preventing reliable follow-up.
Hospital-based adult CKM-related inpatients at the First Affiliated Hospital of Fujian Medical University with available clinical and multimodal examination data for longitudinal registry follow-up.
Cohort
Other
Not listed
First occurrence of a cardiorenal composite endpoint
Time to first occurrence of cardiovascular death or kidney disease progression, defined as sustained decline in eGFR of at least 40% from baseline, sustained eGFR below 15 mL/min/1.73 m², initiation of maintenance dialysis, kidney transplantation, or renal death.
All-cause mortality
Time to death from any cause during follow-up.
3-point major adverse cardiovascular events (3-point MACE)
Time to first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal ischemic stroke.
First hospitalization for heart failure or cardiovascular death
Time to first hospitalization for heart failure or cardiovascular death during follow-up.
Nonfatal Myocardial Infarction
First occurrence of nonfatal myocardial infarction during follow-up.
Incident Malignant Tumor
First occurrence of a newly diagnosed malignant tumor during follow-up.
Incident Dementia Based on Clinical Diagnosis Records
First occurrence of newly diagnosed dementia identified from inpatient or outpatient diagnosis records, discharge records, or follow-up verification during longitudinal follow-up.
Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score
Cognitive decline assessed by change from baseline in Montreal Cognitive Assessment (MoCA) total score during longitudinal follow-up; lower scores indicate worse cognitive performance.
Coronary CTA Imaging Progression
Longitudinal progression of coronary computed tomography angiography findings, including stenosis severity, plaque burden, plaque composition, coronary artery calcium score, CT-QFR, epicardial adipose tissue parameters, and perivascular fat parameters.
Click on the lead sponsor to view all of their trials.
